Karyopharm Therapeutics Inc. KPTI
0.07 USD -0.02 (-17.44%)
At closeNov 4, 2026, 7:59 PM EST
0.08 +0.01 +15.91%
After hours · Nov 4, 7:59 PM ET
0.0729 Day range 0.1268
0.0729 52-week range 10.99
- YTD
- -99.01%
- 1 year
- -98.71%
Analyst view
Price target (mean) 4.50 +6072.8% upside
Now 0.0729
- Target (low)
- 2.00
- Target (mean)
- 4.50
- Target (high)
- 7.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy4
- Buy2
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.2476 | -0.30 – -0.19 | -0.36 | +31.2% | 38.20M | +13.2% | 5 |
| Next quarter | -0.20 | -0.20 – -0.20 | -0.32 | +37.5% | 45.71M | +38.0% | 1 |
| Current year | -0.7452 | -1.06 – -0.606 | -1.25 | +40.4% | 152.89M | +4.7% | 5 |
| Next year | -0.7574 | -1.06 – -0.56 | -0.7452 | -1.6% | 166.13M | +8.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 7, 2024 | Baird | Maintained | Outperform | Outperform |
| Jun 28, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 3, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 3, 2023 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 7, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 3, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 3, 2023 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 3, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 26, 2023 | Wedbush | Maintained | Neutral | Neutral |
| Jul 26, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 18, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 5, 2023 | RBC Capital | Maintained | — | Outperform |
| May 5, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| May 5, 2023 | Baird | Maintained | — | Outperform |
| Apr 19, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 22, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 16, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 27, 2023 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jan 19, 2023 | Piper Sandler | Initiated | — | Overweight |
| Jan 10, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 10, 2023 | SVB Leerink | Maintained | — | Market Perform |
| Nov 4, 2022 | RBC Capital | Upgrade | Sector Perform | Outperform |